HTG2014-Section-Header-publications

Categories

Filter by Topics

ADCC Gene Alteration adolescents ALK Angiogenesis Apoptosis Autocrine Signaling Biology of neoplasia Biomarkers Bladder Cancer Blood Brain Breast Cancer Cardiovascular Disease CDKN2A mutation Cells Chemokines Circulating miRNAs Colorectal cancer Comparison study Core Needle Biopsy COVID-19 Custom mRNA Cytokines Developmental Immunotherapy Developmental Therapeutics Diabetes Differential Expression Differential Gene Expression Analysis DLBCL Drug Response Efficacy EMT Epstein-Barr ERBB3 Esophageal Cancer Exosomes extracellular miRNAs Extracellular Vesicles Feasibility FFPE FGF Ligand Trap FGFR Follicular lymphoma Gene Expression Gene Expression Profiling Gene Fusions Gene Signature Analysis Genetic Polymorphism Genitourinary cancer Head and Neck Cancer Heart HLA-E Homing HPV HTG EdgeSeq ALKPlus Assay EU HTG EdgeSeq DLBCL Cell of Origin Assay HTG EdgeSeq DLBCL Cell of Origin Assay EU HTG EdgeSeq EGFR KRAS and BRAF Mutation Assay HTG EdgeSeq Immune Response Panel HTG EdgeSeq Immuno-Oncology Assay HTG EdgeSeq Immuno-Oncology Panel HTG EdgeSeq Lung Fusion Assay HTG EdgeSeq miRNA Whole Transcriptome Assay HTG EdgeSeq miRNA Whole Transcriptome Panel HTG EdgeSeq Oncology Biomarker Panel HTG EdgeSeq PATH Assay HTG EdgeSeq Precision Immuno-Oncology Panel HTG EdgeSeq System Immune Cells Immune Checkpoint Inhibitors Immune Response Immune System Immuno-Oncology Immunotherapy Integrins Kidney Liposarcoma Liquid Biopsy Liver liver tissue Lung Lupus Lymphocytes Lymphoma Melanoma Mesothelioma Microenvironment miRNA Molecular Characterization Mouse mRNA custom mTOR signaling Multiple Myeloma MYC Natural Killer Cells Neoantigens Novel Therapeutic Targets Oral Cancer Osteoarthritis Pancreas Pathway Analysis Patient Stratification PAXgene PBMCs PCA Cell Lines PD-L1 PFAS PIK3CA mutation Plasma Platform Comparison Programmed cell death protein 1 Prostate Prostate Cancer qNPA qPCR Renal Cell Carcinoma Reproductive Reveal Rheumatoid Arthritis safety Sarcoma Serum Signaling Inhibitors Signaling Pathways Signature Validation Signatures Sinonasal Carcinoma Squamous cell carcinoma Sub-typing Therapeutic Response TMB Toxicity TP53 mutation Transplantation Treatment Outcome Treatment Stratification Tumor Biology Tumor Immunobiology Tumor infiltrating lymphocytes Tumor Microenvironment tumor microenvironment Urine Urothelial carcinoma VEGFR Xenograft Tissue

2014

Blood test to Monitor for the Absence of Acute Cardiac Rejection: From Discovery to Clinical Implementation

Hollander Z., et al. Blood test to Monitor for the Absence of Acute Cardiac Rejection: From Discovery to Clinical Implementation. J Heart Lung Transplant. 2014 Apr; 32(Suppl 4).

View External Link

2013

Development of an automated RNA-based nuclease protection assay for the detection of expressed EML-ALK fusions, EGFR and KRAS mutations in NSCLC.

Rounseville M., et al. Development of an automated RNA-based nuclease protection assay for the detection of expressed EML-ALK fusions, EGFR and KRAS mutations in NSCLC. J Clin Oncol. 2013;31(Suppl); abstr e22185.

View External Link

Targeted gene expression sequencing from FFPE: NPSeq™.

Thompson D., et al. Targeted gene expression sequencing from FFPE: NPSeq™. Cancer Res. 2013;73(8 Suppl):abstr 4146.

View External Link

Array-based Quantitative Nuclease Protection Assay Can Reproducibly Identify Prognostic mRNA Biomarkers in Archival Mantle Cell Lymphoma Specimens

Yang D., et al. Array-based Quantitative Nuclease Protection Assay Can Reproducibly Identify Prognostic mRNA Biomarkers in Archival Mantle Cell Lymphoma Specimens. Mod Pathol. 2013 Feb;26(S2):368A.

Download pdf 1.0MB

Investigation of a Redox-Sensitive Predictive Model of Mouse Embryonic Stem Cell Differentiation via Quantitative Nuclease Protection Assays and Gluthione Redox Status

Chandler K., et al. Investigation of a Redox-Sensitive Predictive Model of Mouse Embryonic Stem Cell Differentiation via Quantitative Nuclease Protection Assays and Gluthione Redox Status. Poster session presented at: 52nd Annual Society of Toxicology Meeting; 2013 Mar 10-14, San Antonio, TX.

View External Link

Automated Measurement of Gene Expression from FFPE: qNPA vs. qPCR

Rounseville M., et al. Automated Measurement of Gene Expression from FFPE: qNPA vs. qPCR. Poster session presented at: Molecular Med Tri-Con; 2013 Feb 11-15; San Francisco, CA

Download pdf 830KB

2012

Measuring molecular biomarkers in epidemiologic studies: laboratory techniques and biospecimen considerations

Erickson H.S. Measuring molecular biomarkers in epidemiologic studies: laboratory techniques and biospecimen considerations. Stat Med. 2012 Sep 28;31(22):2400-13.

PMID: 22593027

View External Link

2011

Quantitative Nuclease Protection Assay (qNPA) for Gene Expression Analysis on Brest Cancer Core Biopsies.

Evangelist M., et al. Quantitative Nuclease Protection Assay (qNPA) for Gene Expression Analysis on Brest Cancer Core Biopsies. J Clin Oncol. 2011 Sep 20;29(Suppl 27);abstr 49.

View External Link

Accurate Classification of Diffuse Large B cell Lymphoma into Germinal Center and Activated B cell Subtypes Using a Nuclease Protection Assay on Paraffin Embedded Tissues.

Rimsza L., et al. Accurate Classification of Diffuse Large B cell Lymphoma into Germinal Center and Activated B cell Subtypes Using a Nuclease Protection Assay on Paraffin Embedded Tissues. Clin Cancer Res. 2011 Jun 1:17(11)

PMID: 21364035

View External Link

Identification of ALK gene alterations in urothelial carcinoma (UC).

Bellmunt, J. Identification of ALK gene alterations in urothelial carcinoma (UC). J Clin Oncol. 2011 Sep 20;29(Suppl 27);abstr 4568. 

View External Link

2010

A Strategy for Full Interrogation of Prognostic Gene Expression Patterns: Exploring the Biology of Diffuse Large B Cell Lymphoma.

Rimsza L, et al. A Strategy for Full Interrogation of Prognostic Gene Expression Patterns: Exploring the Biology of Diffuse Large B Cell Lymphoma. PLoS One. 2011;6(8):e22267.

PMID: 21829609

View External Link

Page last updated October 21, 2021